arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Kiniksa Pharmaceuticals International, plc

KNSA
$76.03 ▼ -0.45 (-0.59%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
37 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
72
Health
Good
Neutral
auto_awesome

Analytical Summary

Kiniksa Pharmaceuticals International, plc shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $5.8B
Dividend Yield
Revenue Growth 55.5%
Op. Margin 13.7%
ROIC 3.3%
FCF / Share $0.65
Trailing P/E 253.4x
Price / Book 9.6x
FCF Yield 0.9%
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

37-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$214.27M
↑ +55.5%
Net Income Profit after all expenses
$22.59M
↑ +164.6%
Operating Margin Operating profit as % of sales
13.7%
↑ +39.7% 60th
FCF / Share Free cash flow per share
$0.65
↑ +113.8%

Health Breakdown

Profitability
68
Returns
69
Cash Quality
88

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 10 years · 37 quarters